Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05791097
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 156
- Registration Number
- NCT05781308
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷CHU Besançon - Hôpital J. MINJOZ, Besançon, France
🇫🇷Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT05775289
- Locations
- 🇲🇽
ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District), Mexico
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain
🇦🇺Monash Health, Clayton, Victoria, Australia
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT05751668
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Morton Plant Hospital, Clearwater, Florida, United States
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 849
- Registration Number
- NCT05747794
- Locations
- 🇺🇸
The Oncology Institute, Whittier, California, United States
🇺🇸The George Washington University Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT05741021
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Imunon
- Target Recruit Count
- 50
- Registration Number
- NCT05739981
- Locations
- 🇺🇸
Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05730777
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Metastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Lip and Oral Cavity Cancer AJCC v8Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 290
- Registration Number
- NCT05721755
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Carle Physician Group-Effingham, Effingham, Illinois, United States
🇺🇸Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 377
- Registration Number
- NCT05722015
- Locations
- 🇭🇺
Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan
🇺🇸St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.